Genentech, UC Settle Suit for $200 Million

See allHide authors and affiliations

Science  26 Nov 1999:
Vol. 286, Issue 5445, pp. 1655
DOI: 10.1126/science.286.5445.1655a

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


SAN FRANCISCO-- Last week, South San Francisco biotech pioneer Genentech agreed to pay the University of California (UC) $200 million to settle a long-running patent suit. UC and Genentech were locked in a court battle over UC's claim that the company's $2 billion drug, Protropin, had infringed its patent on engineered human growth hormone. The deal, which includes a $50 million donation toward a research building at UC San Francisco--the campus that holds the disputed patent--will result in payments of $17 million each to five former UCSF scientists.